logo
Plus   Neg
Share
Email

Kraton Seeking Regulatory Approval For BIAXAM - Quick Facts

Kraton Corp. (KRA) announced Wednesday it is seeking regulatory approval for BIAXAM, a novel sulfonated polymer technology with long-lasting self-disinfecting properties.

The patent-pending technology has demonstrated in studies to quickly inactivate up to 99.99% of SARS-CoV-2 (the COVID-19 virus) and other microbes in as little as 5 minutes.

Kraton developed the BIAXAM technology as part of its sulfonated polymer product line and plans to expand product testing and seek regulatory approval for use as a durable, long-lasting disinfectant from the United States Environmental Protection Agency (EPA).

In parallel, Kraton is pursuing registrations and/or approval with appropriate regulatory agencies in countries outside the U.S.

The efficacy of Kraton's BIAXAM technology has been thoroughly studied by renowned organizations, including Boston University's National Emerging Infectious Diseases Laboratories (NEIDL), North Carolina State University, University of Texas Medical Branch (UTMB) at Galveston, and Syngene International Ltd.

Depending on the regulatory approval process or certification requirements by country, Kraton believes that BIAXAM could be used as a coating on personal protective equipment (PPE).

The BIAXAM technology is patent-pending and will be commercially available shortly. For the U.S. market, until EPA approval is obtained, BIAXAM cannot be sold, marketed or distributed as components of products that kill or repel or claim to kill or repel microbes such as virus, bacteria or mold.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Santa Cruz Bicycles LLC has recalled certain model year 2020 bicycles with aluminum frames citing fall risks, according to the U.S. Consumer Product Safety Commission. The recall involves about 2,900 units of model year 2020 Auminum Santa Cruz and Juliana Bicycles. In addition, about 216 were sold in Canada. AstraZeneca is mulling an additional global trial to confirm the 90% efficacy rate of its Covid-19 vaccine candidate at lower dosage, Bloomberg news quoted Chief Executive Officer Pascal Soriot as saying. In an interview, Soriot noted that instead of adding the trial to an ongoing U.S. process, the company might launch a fresh study to evaluate efficacy of lower dosage of its vaccine that perform U.S. airline Delta Air Lines, Inc. and its Italian codeshare partner Alitalia are planning to launch quarantine-free, COVID-free flights between U.S. and Europe through new testing protocols, starting in December. In a statement, Delta said it has signed deals with airports and governments eliminating quarantine requirements on COVID-tested flights connecting Atlanta and Rome.
Follow RTT